Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors. [electronic resource]
Producer: 20140414Description: ra68 p. digitalISSN:- 1937-9145
- Animals
- Antibodies, Bispecific
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Biomarkers, Tumor -- metabolism
- Breast Neoplasms -- drug therapy
- Computer Simulation
- Feedback, Physiological -- physiology
- Female
- Lapatinib
- MAP Kinase Signaling System -- drug effects
- Mice
- Models, Biological
- Neuregulin-1
- Oncogene Protein v-akt -- antagonists & inhibitors
- Quinazolines
- Receptor, ErbB-2 -- antagonists & inhibitors
- Receptor, ErbB-3 -- antagonists & inhibitors
- Signal Transduction -- physiology
- Trastuzumab
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.